Aortic Stent Market By Product Type (Abdominal Aortic Stents, Thoracic Aortic Stents, Fenestrated Aortic Stents, Covered Stents, Bare Metal Aortic Stents, Drug-Eluting Aortic Stents), By Application (Aortic Aneurysms, Aortic Dissection, Aortic Trauma, Aortic Occlusive Disease, Others), By Material (Nitinol, Stainless Steel, Cobalt-Chromium Alloy, Polymer-Based Stents, Others), By Procedure (Endovascular Aneurysm Repair, Thoracic Endovascular Aneurysm Repair, Open Surgical Repair, Hybrid Procedures), and By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Cardiac & Vascular Research Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Aortic Stent Market in the coming years?

The Aortic Stent Market accounted for USD 3.68 Billion in 2024 and USD 3.94 Billion in 2025 is expected to reach USD 7.76 Billion by 2035, growing at a CAGR of around 7.02% between 2025 and 2035. The aortic stent market deals with the development, production, and selling of stents that are particularly aortic in nature, the largest artery in the body. The main purposes of such stents are in the treatment of conditions such as aortic aneurysms or aortic dissection to strengthen the blood vessel walls and provide adequate circulation. The market encompasses the different kinds of stents, e.g., covered and bare-metal, with the market being motivated by the new developments in medical technology, the growing ageing population, and the ever-growing prevalence of cardiovascular diseases. Another factor that is causing growth in this market is the increased awareness and better methods of diagnosing aortic ailments.

What do industry experts say about the Aortic Stent market trends?

“Aortic stent graft technology has revolutionized the treatment of thoracic and abdominal aortic aneurysms by offering a minimally invasive alternative to open surgery, reducing mortality and recovery time.”

• Dr. Michael Dake, MD (Professor of Cardiothoracic Surgery, University of Arizona)

“Endovascular stent grafting for aortic repair provides significant benefits for high-risk patients, enabling faster mobilization and fewer complications compared to traditional open repair.”

• Dr. Frank Arko, MD (Chief of Vascular and Endovascular Surgery, Sanger Heart & Vascular Institute)

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Aortic Stent market?

How does increasing prevalence of cardiovascular diseases accelerate market growth?

Another major force that increases the aortic stent market growth is the increased prevalence of cardiovascular diseases (CVDs). According to reports by the World Health Organisation (WHO), CVDs are the major cause of mortality in the world, and the number of deaths attributed to CVDs in the world is approximately 17.9 million deaths per year, or about 32% of total world deaths. Of these, the aortic diseases include aortic aneurysms and stenosis, which are significant causes of mortality and disability, particularly in the elderly. In the United States, the U.S. Centers for Disease Control and Prevention (CDC) estimates that almost 10,000 deaths occur every year due to aortic aneurysms.

According to research conducted by the National Institutes of Health (NIH), aortic stenosis affects a significant percentage of the population in old age, with most of the patients having to undergo interventions that would help localise life-threatening complications. This disease burden necessitates the urgent necessity of effective treatment modalities such as aortic stents, which are minimally invasive modalities, and patients with a stent have better patient outcomes, increasing demand and fuelling market development.

Will rising geriatric population enhance demand for aortic stent procedures?

The geriatric population is on the increase, and it is a major driver behind the growing demand for aortic stent procedures. It has been estimated by the United Nations that the world population aged over 60 years will be over 2 billion, which is more than twice the size in 2015. Ageing also raises the incidence of aortic valve disorders, including aortic stenosis, which is estimated to be prevalent in 2% of individuals over 65 and 4% of those over 85.

In the United States and India, the ageing population is widening the number of elderly patients requiring less invasive treatment such as transcatheter aortic valve replacement (TAVR). The National Institutes of Health also reports that the elderly tend to have comorbid cardiovascular conditions that would rather be treated less invasively. The need to obtain access to advanced cardiovascular treatments is ever-increasing as the number of patients receiving aortic stent surgeries is on the rise because of the increased life expectancy, which leads to the rising number of cardiovascular diseases.

Does lack of skilled specialists limit widespread implementation of stent technology?

The scarcity of professional experts is another major setback to the proliferation of the aortic stent technology. The World Health Organisation states that there is a worldwide lack of cardiac surgeons and interventional cardiologists, particularly in low- and middle-income nations, where the ratio of cardiac surgeons to the population is less than 1 to a million, in comparison to more than 7 to the million population of a high-income nation. This affects the ability to carry out complicated procedures such as aortic stenting, which requires specialised training.

The American Heart Association stated that despite the increase in the coronary interventions, little specialisation is available in the training of specialists who specifically specialise in aortic and structural hearts. In other countries like India, there is a ratio of 1:300,000 cardiologists to the population, and accessibility to advanced cardiovascular technologies is restricted. Therefore, the lack of trained specialists is one of the bottlenecks in the implementation of aortic stents despite their clinical benefits.

Could emerging markets provide new avenues for expanding aortic stent sales?

Aortic stents have high growth potential in emerging markets, particularly in light of increased incidences of cardiovascular diseases, as well as the enhancement of infrastructure in the healthcare sector. The World Health Organisation estimates that the death rate of CVDs is more than 80% in the low- and middle-income countries, most of them being in the emerging markets such as India, China, and Brazil. The Ministry of Health in India registers that CVD is a leading cause of nearly 28% of all deaths due to the rising rates of hypertension and diabetes.

The National Health Commission of China underscores the fact that CVD has increased very fast among its ageing population, and more than 300 million individuals are living with the disease. These patterns are the growth of the requirement for sophisticated cardiac procedures, like aortic stents. There is a great amount of new investment in healthcare modernisation and insurance schemes in many emerging economies, where access to devices with high prices is increased. This change is reflected in the growth in the coverage of cardiovascular procedures as a part of the Unified Health System in Brazil. Overall, the increasing disease burden and increased access to healthcare in the emerging markets represent good prospects for aortic stent sales growth in the world market.

Are collaborations between medical device companies likely to spur innovation?

The partnerships of medical device manufacturers, academics, and government agencies are of great significance in the innovation in the aortic stent market. With the integration of clinical knowledge and engineering, and regulatory advice, such alliances speed up the creation of safer and more effective stent grafts. Multidisciplinary research on vascular devices is funded by the U.S. National Institutes of Health to help new designs more quickly translate into clinical practice. The National Science Foundation supports programmes that support industry-academia partnerships to enhance biomaterials and device integration, essential to a complex aortic anatomy.

Studies by the university medical centres, such as Mayo Clinic and Stanford, indicate that collaborative environments cultivate iterative prototyping, which saves time-to-market and improves patient outcomes. The FDA has a Medical Device Innovation Consortium of public-private partnerships and offers a framework that can be used to test new stent technologies efficiently. Such activities can resolve issues such as the longevity of devices and challenges, which are major sources of innovation in the aortic stent sector.

What are the key market segments in the Aortic Stent industry?

Based on the product type, the Aortic Stent Market is classified into Abdominal Aortic Stents, Thoracic Aortic Stents, Fenestrated Aortic Stents, Covered Stents, Bare Metal Aortic Stents, and Drug-Eluting Aortic Stents. The most prevailing product in the aortic stent market is abdominal aortic stents. This tendency is motivated by the fact that abdominal aortic aneurysms (AAAs) are very common, especially in the ageing population.

These stents are mostly applied in the endovascular repair of aneurysms (EVAR), which is an alternative to open surgery, which is more minimally invasive. This has been strengthened by their popularity in the market due to the stent design and patient outcomes, which have enabled them to be the market leaders. The need for abdominal aortic stents is likely to have a steady demand in the future as people across the world grow older.

Based on the application, the Aortic Stent Market is classified into Aortic Aneurysms, Aortic Dissection, Aortic Trauma, Aortic Occlusive Disease, and Others. The most predominant market segment in aortic stents is aortic aneurysms. This is mostly because they are more prevalent than other aortic afflictions, especially among the elderly.

Stent graft endovascular repair has become the most common form of treatment of abdominal and thoracic aneurysms, as this is less invasive and less prone to complications. Such aspects cause the procedures involving aneurysms to be the main demand for aortic stents, surpassing other uses such as dissections or trauma. This segment will continue to lead as screening and diagnosis become better.

Which regions are leading the Aortic Stent market, and why?

The North American aortic stent market is the leading one because of the developed healthcare system and widespread use of new medical technologies. The region has been enjoying in-depth investments in cardiovascular research and the impressive presence of key market players that have spearheaded the development of products. Aortic stenting procedures are demanded because of cardiovascular diseases and ageing populations. Well-established reimbursement policies and widespread awareness among patients and healthcare providers further boost market growth.

The North American regulatory system simplifies the process of approving new devices, making them available to the market faster. An adequate supply of expert surgeons and modern hospitals is also fundamental in spurring market growth. Continuous innovation is aided by clinical trials and cooperation between the medical institutions and industry stakeholders. The high rates of healthcare expenditure and preference by patients to undergo minimally invasive surgeries are driving the demand to cement North America as the leader in this market.

The Asia-Pacific aortic stent market is dominating because of a number of important reasons. The high rate of urbanisation and rising cases of cardiovascular diseases are leading to pressure on the need to seek advanced vascular therapies. Increasing knowledge on minimally invasive procedures and better healthcare infrastructure has opened up the aortic stent interventions. An improved government effort to drive cardiovascular health and the growing disposable income in the emerging developmental economies, such as China and India, contribute to market growth.

The dominance is further enhanced by the presence of a large patient pool and an increased medical device manufacturing capability. In addition, the partnership between domestic and international businesses has enhanced innovation and the supply of products. Overall, a combination of demographic trends, healthcare advancements, and economic growth positions Asia Pacific as a frontrunner in the aortic stent market.

What does the competitive landscape of the Aortic Stent market look like?

The aortic stent market is very competitive with innovation and wideness of the wide clinical use. Medtronic, Terumo Corporation, Boston Scientific, Abbott Laboratories, and MicroPort are among the major players that are continually improving their device technologies to ensure patients have a better chance of survival, coupled with providing more treatment options for complex aortic diseases. Recent trends reflect a high trend in the development of low-profile, highly flexible stent grafts that can be used in minimally invasive procedures and thereby reduce the recovery time and complications. Firms are also pursuing regulatory approvals in the world markets as well, so as to expand their sphere.

Joint ventures and acquisitions are popular measures that can be taken to reinforce product lines and hasten innovation. This dynamic space challenges the players to enhance product performance but also respond to the needs of niche patients, which stimulates continuous development of the market. Market opportunities are likely to increase with the growing incidence of aortic ailments and the development of improved imaging technologies. Since patient safety and the period following the surgery have become prime issues, businesses are increasingly focusing on developing stents with better long-term results.

Aortic Stent Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Aortic Stent industry?

• In August 2024, Terumo India launched the TREO® Stent-Graft System, a new endovascular aneurysm repair (EVAR) graft designed for infrarenal abdominal aortic aneurysms. It featured unique aspects like active fixation for both suprarenal and infrarenal areas, in-situ limb adjustability, improved proximal sealing, and better adaptability for complex anatomies.

Report Coverage:

By Product Type

• Abdominal Aortic Stents
• Thoracic Aortic Stents
• Fenestrated Aortic Stents
• Covered Stents (Stent Grafts)
• Bare Metal Aortic Stents
• Drug-Eluting Aortic Stents

By Application

• Aortic Aneurysms
• Aortic Dissection
• Aortic Trauma
• Aortic Occlusive Disease
• Others

By Material

• Nitinol
• Stainless Steel
• Cobalt-Chromium Alloy
• Polymer-Based Stents
• Others

By Procedure

• Endovascular Aneurysm Repair (EVAR)
• Thoracic Endovascular Aneurysm Repair (TEVAR)
• Open Surgical Repair
• Hybrid Procedures

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Cardiac & Vascular Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic
• Cook Medical
• W.L. Gore & Associates
• Terumo Corporation
• Boston Scientific
• Abbott Laboratories
• Cardinal Health
• Endologix
• MicroPort Scientific Corporation
• Lombard Medical
• JOTEC GmbH
• CryoLife
• Braile Biomedica
• Merit Medical Systems
• Biotronik SE & Co. KG

Frequently Asked Questions (FAQs)